IC
VKTX icon

Ikarian Capital’s Viking Therapeutics VKTX Stock Holding History

Ikarian Capital’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-200,000
Closed -$16.4M – 155
2024
Q1 		$16.4M Buy
+200,000
New +$8.9M 1.8% 15
2020
Q1 		– Sell
-150,000
Closed -$1.2M – 174
2019
Q4 		$1.2M Buy
+150,000
New +$1.09M 0.19% 76

Other funds holding VKTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Ikarian Capital's VKTX Position: Q1 2026 in Review

Ikarian Capital held its Viking Therapeutics (VKTX) position steady in Q1 2026 at 9,717 shares worth $316K. The position accounts for 0.03% of the portfolio, ranked #132.

Ikarian Capital first reported a position in VKTX in Q4 2019 and has held it in 18 quarters since. The position peaked at $7.33M in Q2 2024. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • Ikarian Capital held 9,717 shares of Viking Therapeutics worth $316K as of Q1 2026.
  • Ikarian Capital left its Viking Therapeutics share count unchanged in Q1 2026.
  • Viking Therapeutics made up 0.03% of Ikarian Capital's portfolio in Q1 2026, its #132 holding.
  • Ikarian Capital first reported a position in Viking Therapeutics in Q4 2019 and has held it in 18 quarters since.
  • Ikarian Capital's Viking Therapeutics position peaked at $7.33M in Q2 2024.
  • 410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.